Rapamycin-induced phosphaturia

Nephrology Dialysis Transplantation

Volumn 25, Issue 9, 2010, Pages 2938-2944

  Kempe, Daniela S ^a   Dërmaku Sopjani, Miribane ^a   Fröhlich, Henning ^a   Sopjani, Mentor ^a   Umbach, Anja ^a   Puchchakayala, Goverdhan ^a   Capasso, Anna ^a   Weiss, Florian ^a   Stübs, Michael ^a   Föller, Michael ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

1,25(OH)2D3; mTOR; NaPi IIa; phosphate; PTH

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS;

ANIMALS; BIOLOGICAL TRANSPORT; FEMALE; HYPOPHOSPHATEMIA, FAMILIAL; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MICE; OOCYTES; PHOSPHATES; RATS; SIROLIMUS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIA; TOR SERINE-THREONINE KINASES; XENOPUS LAEVIS;

EID: 77956250098     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq172     Document Type: Article

References (60)

1. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008; 1: 27-36
2. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112
3. Delgoffe GM, Powell JD. mTOR: taking cues from the immune microenvironment. Immunology 2009; 127: 459-465
4. Prlic M, Bevan MJ. Immunology: a metabolic switch to memory. Nature 2009; 460: 41-42
5. Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064
6. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644
7. Martelli AM, Evangelisti C, Chiarini F et al. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009; 18: 1333-1349
8. Scott KL, Kabbarah O, Liang MC et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009; 459: 1085-1090
9. Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 2009; 13: 1193-1203
10. Paoletti E, Cannella G. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. Transplant Proc 2009; 41: S3-S5
11. Chapman AB. Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol 2007; 18: 1399-1407
12. Fischer DC, Jacoby U, Pape L et al. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 2009; 24: 1819-1827
13. Zafar I, Belibi FA, He Z, Edelstein CL. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 2009; 24: 2349-2353
14. Harrison DE, Strong R, Sharp ZD et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395
15. Goberdhan DC, Boyd CA. mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans 2009; 37: 213-216
16. Proud CG. Amino acids and mTOR signalling in anabolic function. Biochem Soc Trans 2007; 35: 1187-1190
17. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005; 17: 158-166
18. Ueno M, Carvalheira JB, Tambascia RC et al. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 2005; 48: 506-518
19. Mezey E, Rennie-Tankersley L, Potter JJ. Effect of leptin on liver alcohol dehydrogenase. Biochem Biophys Res Commun 2005; 337: 1324-1329
20. Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 2005; 12: 1344-1357
21. Wouters BG, van Den BT, Magagnin MG et al. Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev Biol 2005; 16: 487-501
22. Peyrollier K, Hajduch E, Blair AS, Hyde R, Hundal HS. L-Leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport. Biochem J 2000; 350: 361-368
23. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008; 416: 375-385
24. Lang F, Bohmer C, Palmada M et al. (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006; 86: 1151-1178
25. Shojaiefard M, Lang F. Stimulation of the intestinal phosphate transporter SLC34A2 by the protein kinase mTOR. Biochem Biophys Res Commun 2006; 345: 1611-1614
26. Schwarz C, Bohmig GA, Steininger R, Mayer G, Oberbauer R. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001; 16: 378-382
27. Bielesz B, Klaushofer K, Oberbauer R. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 2004; 35: 1229-1239
28. El Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66
29. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-1059
30. Li X, Giachelli CM. Sodium-dependent phosphate cotransporters and vascular calcification. Curr Opin Nephrol Hypertens 2007; 16: 325-328
31. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51
32. Kurosu H, Kuro-o M. The Klotho gene family and the endocrine fibroblast growth factors. Curr Opin Nephrol Hypertens 2008; 17: 368-372
33. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007; 69: 341-359
34. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373-1409
35. Takeda E, Taketani Y, Sawada N, Sato T, Yamamoto H. The regulation and function of phosphate in the human body. Biofactors 2004; 21: 345-355
36. Forster IC, Hernando N, Biber J, Murer H. Proximal tubular handling of phosphate: a molecular perspective. Kidney Int 2006; 70: 1548-1559
37. Biber J, Hernando N, Forster I, Murer H. Regulation of phosphate transport in proximal tubules. Pflugers Arch 2009; 458: 39-52
38. Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch 2004; 447: 763-767
39. Villa-Bellosta R, Ravera S, Sorribas Vet al. The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. Am J Physiol Renal Physiol 2009; 296: F691-F699
40. Allon M. Effects of insulin and glucose on renal phosphate reabsorption: interactions with dietary phosphate. J Am Soc Nephrol 1992; 2: 1593-1600
41. DeFronzo RA, Goldberg M, Agus ZS. The effects of glucose and insulin on renal electrolyte transport. J Clin Invest 1976; 58: 83-90
42. Feld S, Hirschberg R. Insulinlike growth factor I and the kidney. Trends Endocrinol Metab 1996; 7: 85-93
43. Lang F, Cohen P. Regulation and physiological roles of serum-and glucocorticoid-induced protein kinase isoforms. Sci STKE 2001; 2001: RE17
44. Busch AE, Wagner CA, Schuster A et al. Properties of electrogenic Pi transport by a human renal brush border Na+/Pi transporter. J Am Soc Nephrol 1995; 6: 1547-1551
45. Strutz-Seebohm N, Gutcher I, Decher N et al. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell Physiol Biochem 2007; 20: 791-800
46. Wagner CA, Friedrich B, Setiawan I, Lang F, Broer S. The use of Xenopus laevis oocytes for the functional characterization of heterologously expressed membrane proteins. Cell Physiol Biochem 2000; 10: 1-12
47. Boehmer C, Laufer J, Jeyaraj S et al. Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell Physiol Biochem 2008; 22: 591-600
48. Boehmer C, Palmada M, Klaus F et al. The peptide transporter PEPT2 is targeted by the protein kinase SGK1 and the scaffold protein NHERF2. Cell Physiol Biochem 2008; 22: 705-714
49. Vallon V. In vivo studies of the genetically modified mouse kidney. Nephron Physiol 2003; 94: 1-5
50. Lang PA, Warskulat U, Heller-Stilb B et al. Blunted apoptosis of erythrocytes from taurine transporter deficient mice. Cell Physiol Biochem 2003; 13: 337-346
51. Bayrakci US, Baskin E, Ozcay F et al. Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy? Pediatr Transplant 2008; 12: 109-112
52. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M. Tubular toxicity in sirolimus-and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010; 55: 335-343
53. Whiting PH, Adam BJ, Woo J, Hasan NU, Thomson AW. The effect of rapamycin on renal function in the rat: a comparative study with cyclosporine. Toxicol Lett 1991; 58: 169-179
54. Perwad F, Azam N, Zhang MY et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1, 25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146: 5358-5364
55. Kato S. Genetic mutation in the human 25-hydroxyvitamin D3 1alpha-hydroxylase gene causes vitamin D-dependent rickets type I. Mol Cell Endocrinol 1999; 156: 7-12
56. Portale AA, Miller WL. Human 25-hydroxyvitamin D-1alphahydroxylase: cloning, mutations, and gene expression. Pediatr Nephrol 2000; 14: 620-625
57. Inoue Y, Segawa H, Kaneko I et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005; 390: 325-331
58. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol 2009; 296: F470-F476
59. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1, 25-dihydroxyvitamin D(2) and 1, 25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-284
60. Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol 2003; 196: 180-189